Publications:34
Camelia Iancu-Rubin, PhD
About Me
Dr. Iancu-Rubin completed her Bachelor and Master degrees in biology at the University of Bucharest in Romania. She started her career in clinical laboratory and teaching then pursued graduate studies in Biomedical Sciences as Fulbright Scholar. Dr. Iancu-Rubin received her PhD Summa Cum Laude from the University of Bucharest and completed a 5-year postdoctoral fellowship in the Division of Hematology at the Mount Sinai Medical Center in New York. She is currently a Professor in the Department of Pathology, Molecular and Cell-Based Medicine and member of the Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai. Dr. Iancu-Rubin has been leading investigator on NIH-funded, foundations and institutional projects as well as on industry-sponsored studies. Her research focuses on preclinical and clinical development of hematopoietic stem cell-based therapies for patients with blood disorders. Dr. Iancu-Rubin is the Director of the Cellular Therapy Laboratory which supports hematopoietic stem cells transplantation services and other cell-based therapies at Mount Sinai Hospital.
Language
English
Position
PROFESSOR | Pathology, Molecular and Cell Based Medicine
Research Topics
Blood, Cancer, Cell Biology, Differentiation, Fibrosis, Hematopoiesis, Leukemia, Molecular Biology, Translational Research
Education
MS, University of Medicine and Pharmacy
PhD, University of Bucharest
, Mount Sinai School of Medicine
Awards
2010
The Tisch Cancer Institute Development Award
Mount Sinai School of Medicine
2007
Mentored Scientist Career Development Award
NIH/NIDDK
1997
Fulbright Fellowship in Biomedical Sciences
IIE/CUNY Mount Sinai Graduate School of Biomedical Sciences
Research
Megakaryocytes and Platelets
Cellular Therapies
Normal and Malignant Hematopoiesis
Publications
Selected Publications
- Hematopoietic Progenitor Cell Products Derived From Bone Marrow and Peripheral Blood. Camelia Iancu-Rubin, Rona Singer Weinberg.
- Overview of Cellular Therapy. Camelia Iancu-Rubin, Rona Singer Weinberg.
- Cryopreservation of Allogeneic Hematopoietic Cell Products During COVID-19 Pandemic: Graft Characterization and Engraftment Outcomes. Alla Keyzner, Jacques Azzi, Rita Jakubowski, Yelena Sinitsyn, Sharon Tindle, Svitlana Shpontak, Deukwoo Kwon, Luis Isola, Camelia Iancu-Rubin. Transplantation Proceedings
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Iancu-Rubin has not yet completed reporting of Industry relationships.
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.